QRICH1-Driven ER Stress Promotes HMGB1 Secretion in HBV Fibrosis

Study Background and Research Question

Hepatitis B virus (HBV) infection remains a leading cause of chronic liver disease and hepatic fibrosis worldwide. A central feature of fibrosis progression is the dysregulated secretion of high mobility group box 1 (HMGB1), a nuclear protein that, once released extracellularly, acts as a damage-associated molecular pattern (DAMP) and amplifies inflammatory and fibrotic responses. Despite growing recognition of HMGB1’s pathological role, the upstream regulatory mechanisms dictating its secretion during HBV-induced hepatic injury are incompletely understood. Endoplasmic reticulum (ER) stress—a disruption in ER homeostasis marked by the accumulation of misfolded proteins—has been implicated in chronic liver conditions, but its precise effectors and downstream consequences in this context require clarification.

The reference study focuses on the role of glutamine-rich 1 (QRICH1), a newly identified effector of ER stress, in mediating HBV-driven HMGB1 translocation and secretion in hepatocytes, and addresses whether QRICH1 acts as a molecular bridge linking ER stress to the progression of hepatic fibrosis (Feng et al., 2025).

Key Innovation from the Reference Study

The major innovation of this work lies in its identification of QRICH1 as a pivotal modulator that enhances HBV-induced HMGB1 secretion through dual regulation: (1) transcriptional upregulation of HMGB1 and (2) facilitation of HMGB1 acetylation-dependent cytoplasmic translocation. The study demonstrates that QRICH1 expression is elevated in both chronic HBV mouse models and human patients with severe fibrosis, and that its levels strongly correlate with increased HMGB1 secretion. Notably, QRICH1 regulates Sirtuin6 (SIRT6), influencing HMGB1 acetylation and subsequent release, thereby establishing a functional link between ER stress signaling and the pathogenic extracellular release of HMGB1. This mechanistic insight clarifies how ER stress, via QRICH1, exacerbates fibrotic progression in HBV-infected livers (Feng et al., 2025).

Methods and Experimental Design Insights

The researchers employed a multifaceted experimental approach combining in vivo, ex vivo, and clinical analyses:

• Chronic rcccDNA Mouse Model: Mice harboring recombinant covalently closed circular DNA (rcccDNA) mimicked chronic HBV infection and hepatic fibrosis. ER stress was induced and modulated pharmacologically.
• Human Clinical Specimens: Liver biopsies and sera from HBV-infected patients with varying fibrosis grades (obtained from Zhongshan Hospital, Fudan University) provided translational relevance. QRICH1 and HMGB1 expression were assessed using immunohistochemistry.
• Biochemical and Molecular Analyses: HMGB1 localization and secretion were quantified via Western blotting, qRT-PCR, and ELISA. Liver collagen deposition, indicating fibrosis, was evaluated by Sirius red and Masson's trichrome staining.
• Mechanistic Interrogation: SIRT6 levels and HMGB1 acetylation status were examined to delineate the pathway by which QRICH1 controls HMGB1 translocation.

This rigorous design allowed the team to dissect causality and correlation across molecular, cellular, and tissue levels, strengthening the study’s translational validity (Feng et al., 2025).

Core Findings and Why They Matter

• ER Stress Aggravates HBV-Induced Fibrosis: Pharmacological induction of ER stress in rcccDNA mice led to significantly worsened hepatic fibrosis, as evidenced by increased collagen deposition and elevated serum HMGB1 (Feng et al., 2025).
• QRICH1 and HMGB1 Levels Are Positively Correlated: Both in mouse models and human patients, higher QRICH1 expression tracked with elevated HMGB1 secretion and more severe fibrotic pathology.
• HBV Modulates SIRT6 and HMGB1 Acetylation: HBV infection decreased SIRT6 expression, promoting HMGB1 acetylation, which is critical for its translocation from nucleus to cytoplasm and eventual secretion.
• QRICH1 Drives HMGB1 Transcription and Secretion: QRICH1 upregulation facilitated increased HMGB1 transcription and enhanced its cytoplasmic export, amplifying pro-inflammatory and profibrotic signaling.
• Clinical Relevance: These molecular findings were mirrored in fibrotic liver biopsies from HBV patients, underscoring the translational importance of the QRICH1–HMGB1 axis in disease progression.

Overall, these results reveal QRICH1 as a nodal point in the ER stress response that promotes HMGB1-driven hepatic fibrogenesis, suggesting new avenues for targeted intervention in chronic HBV infection (Feng et al., 2025).

Comparison with Existing Internal Articles

Internal resources from APExBIO and associated expert guides have previously explored the utility of Tetracycline as a broad-spectrum polyketide antibiotic in ribosomal function research, antibiotic selection, and membrane integrity assays (internal_article_1, internal_article_4). Notably, one article highlights the emerging application of tetracycline in ER stress research, underscoring its value in dissecting protein synthesis and stress pathway modulation in eukaryotic systems. While the present reference study focuses on a viral and fibrotic model in hepatocytes, the mechanistic approaches—such as monitoring protein localization, transcriptional regulation, and post-translational modifications—share methodological overlap with those used in ribosomal and ER stress studies enabled by tetracycline. These established workflows provide a foundation for researchers to translate similar strategies into the study of host-pathogen interactions and organ-specific stress responses.

Protocol Parameters

• ribosomal function assay | 0.5–10 μg/mL tetracycline | bacterial/eukaryotic cell cultures | optimized for inhibition of bacterial protein synthesis, and as an antibiotic selection marker in molecular biology | workflow_recommendation
• cell viability assessment | ≤10 μg/mL tetracycline | mammalian cell lines | recommended to minimize cytotoxicity while enabling selection | internal_article_3
• antibiotic selection marker use | 1–2 μg/mL tetracycline | plasmid maintenance in engineered cells | ensures efficient selection pressure for vectors with tetracycline resistance | internal_article_5
• storage conditions | -20°C (powder), immediate use for solutions | all experimental setups | maintains compound stability and activity | product_spec
• tetracycline solubility | ≥74.9 mg/mL in DMSO; insoluble in water/ethanol | stock solution preparation | facilitates rapid dissolution and accurate dosing in screening assays | product_spec

Limitations and Transferability

While the reference study provides compelling evidence for QRICH1’s role in HBV-induced HMGB1 secretion, several limitations warrant consideration:

• Model Specificity: Findings are based primarily on chronic HBV mouse models and human liver samples from a single clinical center. Broader validation in diverse patient populations and other etiologies of liver disease is needed.
• Mechanistic Breadth: The focus on QRICH1–SIRT6–HMGB1 signaling, while detailed, may not capture the full complexity of ER stress and DAMP pathways in hepatic fibrosis. Additional modulators or compensatory mechanisms may exist.
• Therapeutic Translation: Direct manipulation of QRICH1 or SIRT6 in vivo poses technical and safety challenges. Further preclinical and translational studies are necessary before clinical application (Feng et al., 2025).

Why this cross-domain matters, maturity, and limitations

The integration of advanced molecular biology tools—such as those developed for ribosomal function and ER stress research using broad-spectrum antibiotics like tetracycline—enables precise interrogation of protein synthesis, stress responses, and host-pathogen interactions in diverse systems. However, direct extrapolation from in vitro ER stress models to complex in vivo disease settings (e.g., viral hepatitis, organ fibrosis) requires careful methodological adaptation and rigorous validation, as highlighted by the reference study’s translational approach (internal_article_4, Feng et al., 2025).

Research Support Resources

Researchers aiming to replicate or extend studies of ER stress, protein translocation, or ribosomal function can utilize Tetracycline (SKU C6589), a high-purity, broad-spectrum polyketide antibiotic supplied with rigorous quality documentation. APExBIO’s offering facilitates antibiotic selection, ribosomal function research, and membrane integrity assays, with optimal solubility in DMSO and recommended storage at -20°C for maximal stability (source: product_spec). For protocol details and troubleshooting, see related guides on the use of tetracycline in advanced microbiological and ER stress workflows (internal_article_4).